AlloVir, Inc. (NASDAQ:ALVR - Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 3,950,000 shares, a decrease of 19.2% from the October 15th total of 4,890,000 shares. Based on an average trading volume of 256,400 shares, the days-to-cover ratio is currently 15.4 days.
Institutional Trading of AlloVir
Several institutional investors and hedge funds have recently added to or reduced their stakes in ALVR. Acadian Asset Management LLC raised its position in shares of AlloVir by 694.6% during the first quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company's stock worth $1,197,000 after purchasing an additional 1,387,666 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of AlloVir by 127.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company's stock valued at $74,000 after acquiring an additional 54,900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of AlloVir during the second quarter valued at $55,000. Finally, Cubist Systematic Strategies LLC increased its holdings in AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company's stock worth $36,000 after buying an additional 30,072 shares during the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.
AlloVir Price Performance
Shares of NASDAQ:ALVR traded up $0.03 during trading hours on Friday, hitting $0.58. The stock had a trading volume of 386,619 shares, compared to its average volume of 619,426. The stock's fifty day simple moving average is $0.79 and its 200 day simple moving average is $0.77. AlloVir has a 1-year low of $0.53 and a 1-year high of $2.49.
AlloVir (NASDAQ:ALVR - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10.
AlloVir Company Profile
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AlloVir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list.
While AlloVir currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
